MODERN METHODS OF PHARMACOLOGICAL SCREENING IN EARLY DRUG DISCOVERY

Authors

  • Johannes M. Weber Department of Experimental Pharmacology, Berlin Institute of Biomedical Sciences, Germany

Keywords:

drug discovery; pharmacological screening; high-throughput screening; phenotypic screening; high-content screening; artificial intelligence; organoids; microphysiological systems; ADME/Tox.

Abstract

Early drug discovery increasingly depends on integrated pharmacological screening systems that combine throughput, mechanistic confidence, chemical diversity, human relevance and early developability assessment. This structured review evaluates modern screening methods used to identify and prioritize bioactive compounds before hit-to-lead optimization. The analysis covers high-throughput and quantitative high-throughput screening (HTS/qHTS), target-based and phenotypic strategies, high-content imaging, fragment-based and biophysical screening, artificial-intelligence-assisted virtual screening, secondary pharmacology, early ADME/toxicity assessment, organoids and microphysiological systems. Fifteen international peer-reviewed sources were synthesized within an IMRAD framework. The reviewed evidence shows that scalable biochemical assays remain highly effective for well-validated targets, whereas phenotypic and high-content approaches provide richer information on pathway and cellular responses. Fragment-based screening can efficiently explore chemical space when sensitive biophysical confirmation is available. Artificial intelligence can prioritize very large molecular libraries and support molecular design, but its predictions require prospective experimental validation and careful control of data bias. Organoid and organ-on-chip technologies increase physiological relevance and may improve translational decision-making, although throughput, reproducibility and standardization remain limiting factors. The most robust strategy is therefore a tiered screening cascade integrating assay qualification, orthogonal confirmation, counter-screening, target engagement, selectivity, safety, pharmacokinetics and increasingly human-relevant models. Modern pharmacological screening should be viewed as a decision system rather than a single assay, with evidence quality and reproducibility treated as core pharmacological endpoints.

References

1.Inglese, J., Auld, D. S., Jadhav, A., Johnson, R. L., Simeonov, A., Yasgar, A., Zheng, W., & Austin, C. P. (2006). Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proceedings of the National Academy of Sciences of the United States of America, 103(31), 11473-11478. https://doi.org/10.1073/pnas.0604348103

2.Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? Nature Reviews Drug Discovery, 10(7), 507-519. https://doi.org/10.1038/nrd3480

3.Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Del Nery, E., Ebner, D., et al. (2016). Screening out irrelevant cell-based models of disease. Nature Reviews Drug Discovery, 15(11), 751-769. https://doi.org/10.1038/nrd.2016.175

4.Lin, S., Schorpp, K., Rothenaigner, I., & Hadian, K. (2020). Image-based high-content screening in drug discovery. Drug Discovery Today, 25(8), 1348-1361. https://doi.org/10.1016/j.drudis.2020.06.001

5.Pak, C., Simpson, K. J., Weston, A. D., Cvijic, M. E., Evans, K., & Napper, A. D. (2024). Perspectives on phenotypic screening-Screen Design and Assay Technology Special Interest Group. SLAS Discovery, 29(2), 100146. https://doi.org/10.1016/j.slasd.2024.02.001

6.Catacutan, D. B., Alexander, J., Arnold, A., & Stokes, J. M. (2024). Machine learning in preclinical drug discovery. Nature Chemical Biology, 20(8), 960-973. https://doi.org/10.1038/s41589-024-01679-1

7.Brennan, R. J., Jenkinson, S., Brown, A., Delaunois, A., Dumotier, B., Pannirselvam, M., et al. (2024). The state of the art in secondary pharmacology and its impact on the safety of new medicines. Nature Reviews Drug Discovery, 23(7), 525-545. https://doi.org/10.1038/s41573-024-00942-3

8.Wang, N., Li, X., Xiao, J., Liu, S., & Cao, D. (2024). Data-driven toxicity prediction in drug discovery: Current status and future directions. Drug Discovery Today, 29, 104195. https://doi.org/10.1016/j.drudis.2024.104195

9.Gopallawa, I., Gupta, C., Jawa, R., Cyril, A., Jawa, V., Chirmule, N., & Gujar, V. (2024). Applications of organoids in advancing drug discovery and development. Journal of Pharmaceutical Sciences, 113(9), 2659-2667. https://doi.org/10.1016/j.xphs.2024.06.016

10.Kimura, H., Nishikawa, M., Kutsuzawa, N., Tokito, F., Kobayashi, T., Kurniawan, D. A., et al. (2025). Advancements in microphysiological systems: Exploring organoids and organ-on-a-chip technologies in drug development - focus on pharmacokinetics related organs. Drug Metabolism and Pharmacokinetics, 60, 101046. https://doi.org/10.1016/j.dmpk.2024.101046

11.Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., et al. (2025). Integrating artificial intelligence in drug discovery and early drug development: A transformative approach. Biomarker Research, 13, 45. https://doi.org/10.1186/s40364-025-00758-2

12.Roy, S., Nagaraj, K., et al. (2025). Artificial intelligence in virtual screening: Transforming drug research and discovery-a review. Journal of Bio-X Research, 8, 0041. https://doi.org/10.34133/jbioxresearch.0041

13.Wittich, A., Krieg, K., Gribbon, P., Metzger, J. J., Prigione, A., & Pless, O. (2026). Human organoids: Fit for drug discovery? Stem Cell Reports, 21(6), 102898. https://doi.org/10.1016/j.stemcr.2026.102898

14.Song, C., Li, T., Guan, H., Zhang, T., Zhu, J., Lei, J., et al. (2026). Artificial intelligence-augmented organ- and organoid-on-a-chip for drug screening. Lab on a Chip, 26(16), 4384-4417. https://doi.org/10.1039/D6LC00365F

15.Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016). Twenty years on: The impact of fragments on drug discovery. Nature Reviews Drug Discovery, 15(9), 605-619. https://doi.org/10.1038/nrd.2016.109

Published

2026-09-23